Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure

@article{Rychli2011HepatocyteGF,
  title={Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure},
  author={Kathrin Rychli and Bernhard Richter and Philipp J Hohensinner and Kariem Mahdy Ali and Stephanie Neuhold and Gerlinde Zorn and Rudolf Berger and Deddo M{\"o}rtl and Kurt Huber and R. Pacher and Johann Wojta and Alexander Niessner and Martin H{\"u}lsmann},
  journal={Heart},
  year={2011},
  volume={97},
  pages={1158 - 1163}
}
Objective To assess the prognostic value of the mitogenic, antiapoptotic, angiogenic and antifibrotic hepatocyte growth factor (HGF) in heart failure (HF). Design Prospective cohort study. Setting/patients Assessment of HGF levels at inclusion in 351 patients with advanced HF (median 75 years, interquartile range (IQR) 63–82, 66% male). Main outcome measures All-cause mortality, cardiovascular mortality. Results During a median follow-up of 16 months, 26% of patients died. HGF tertiles were… Expand
Usefulness of the Hepatocyte Growth Factor as a Predictor of Mortality in Patients Hospitalized With Acute Heart Failure Regardless of Ejection Fraction.
TLDR
In patients with acute HF, serum HGF concentrations are elevated and identify patients at higher risk of mortality, regardless of LVEF, ischemic origin, or renal function, and the addition of HGF improved the predictive ability of the models. Expand
Hepatocyte Growth Factor and Incident Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA).
TLDR
HGF remained significantly associated with HFpEF but not HFrEF upon subtype assessment and future studies should examine mechanisms underlying these associations and evaluate whether HGF can be used to improve HF risk prediction or direct therapy. Expand
Hepatocyte growth factor as a long‑term predictor for total and cardiovascular mortality in patients on peritoneal dialysis.
TLDR
Increased concentrations of proinflammatory cytokines and an association between HGF levels and CaSc may indicate higher total and CV mortality in patients on peritoneal dialysis during 6‑year follow-up. Expand
Prognostic Significance of Circulating Levels of Hepatocyte Growth Factor in Patients with Chagas’ Disease and Idiopathic Dilated Cardiomyopathy
TLDR
Although HGF can be significantly increased in advanced HF patients with CD and DCM, its prognostic value for endpoints is minor, and the formerly described predictive power for HGF in HF might be restricted to specific etiologies of HF. Expand
A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure.
TLDR
Risk prediction by a multi-biomarker score is superior to a conventional risk score including clinical parameters and NT-proBNP and additional predictive information from different biological pathways reflects the multisystemic character of HF. Expand
Hepatocyte Growth Factor as a Prognostic Marker in Heart Failure: Promise and Challenges
TLDR
Investigation of the prognostic value of hepatocyte growth factor (HGF) in 91 patients with Chagas’ disease and 47 patients with DCM, evaluated for left ventricular dysfunction found its levels were significantly increased in advanced heart failure patients. Expand
Novel Biomarkers in Cardiac Resynchronization Therapy: Hepatocyte Growth Factor Is an Independent Predictor of Clinical Outcome.
TLDR
Of the investigated biomarkers, only HGF predicted clinical outcomes following CRT independently of other parameters, and reclassification analyses showed that HGF measurements could be useful in refining patient selection. Expand
Utility of Hepatocyte Growth Factor as a Biomarker for Early Diagnosis of Pulmonary Artery Hypertension
TLDR
Plasma levels of HGF in PAH patients with mild disease were significantly higher than those in healthy controls, suggesting that plasma HGF has potential utility as a diagnostic biomarker for early PAH. Expand
Hepatocyte growth factor demonstrates racial heterogeneity as a biomarker for coronary heart disease
TLDR
Evidence that HGF is a biomarker of atherosclerotic disease that is independent of traditional risk factors is provided, as the results are most compelling in African-Americans and non-Hispanic white Americans. Expand
Association of Circulating Hepatocyte Growth Factor and Risk of Incident Peripheral Artery Disease: The Multi-Ethnic Study of Atherosclerosis
TLDR
Higher HGF levels were modestly associated with an increased risk of developing clinical PAD, after adjustment for demographic and clinical variables. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 36 REFERENCES
Prognostic value of apoptosis markers in advanced heart failure patients.
AIMS Apoptosis plays an important role in the progression of heart failure (HF). The purpose of this study was to assess whether the pro-apoptotic molecules apoptosis-stimulating fragment (FAS,Expand
Prognostic value of pigment epithelium-derived factor in patients with advanced heart failure.
TLDR
Experimental data revealed that PEDF may contribute to the progression of HF by inducing apoptosis in human cardiac myocytes and fibroblasts via activation of caspase 3. Expand
Macrophage-modulating cytokines predict adverse outcome in heart failure.
TLDR
The independent and concentration-dependent association of macrophage-modulating cytokines and in particular of M-CSF with adverse outcome in advanced HF patients suggests that these cytokines may play an important pathophysiological role in progression of cardiomyopathy. Expand
Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure.
TLDR
Hematocyte growth factor levels correlate with CHF severity and are associated with an increased cardiovascular mortality during follow-up, which is associated with a worse outcome for patients with high HGF concentrations at baseline. Expand
Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure.
TLDR
Low sTWEAK levels independently predict mortality in advanced non-ischemic HF, and sT WEAK-induced proliferation of cardiomyocytes may explain its impact on suvival. Expand
Serum hepatocyte growth factor levels are increased in patients with congestive heart failure.
TLDR
Serum HGF levels in serum are increased in patients with acute exacerbation of CHF, and levels in the PBMC culture medium were also significantly increased in CHF patients compared with control subjects. Expand
Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure.
TLDR
Impaired HGF production was restored after the treatment with ACE-I probably by the mechanism of Ang II suppression, which may contribute to the clinical improvement in patients with heart failure and thereby may have an important therapeutic implication. Expand
Gene Transfer of Hepatocyte Growth Factor Attenuates Postinfarction Heart Failure
TLDR
Hepatocyte Growth Factor gene transfer following a large myocardial infarction results in significantly preserved myocardIAL function and geometry, and is associated with significant angiogenesis and a reduction in apoptosis. Expand
Vascular endothelial growth factor and soluble P-selectin in acute and chronic congestive heart failure.
TLDR
Levels of vascular endothelial growth factor (VEGF), associated with angiogenesis, were measured in the plasma of patients with varying degrees of CHF and compared levels with those in healthy controls and tested the hypothesis of a link between VEGF and platelet activation and a tendency to hypercoagulability in CHF. Expand
Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients.
TLDR
Serial monitoring for per cent change in NT-proBNP concentrations offers superior prognostic information to clinical assessment among outpatients with recent destabilized HF. Expand
...
1
2
3
4
...